Going concern and liquidity risk
The company depends on external financing and product monetization to fund operations.
- Scope
- Cash on hand and working capital
- Materiality
- high
Vystar Corp
Vystar Corp is a U.S.-based company built around two product families: Vytex natural rubber latex materials and RxAir UV-C air purification devices. Its business combines materials development, product commercialization, and licensing/distribution activities across industrial, healthcare, and consumer-oriented end markets.
−1 811,5 %
58,0 %
−2 793,9 %
−59,7 %
0.05
0.05
| % | |
|---|---|
| Vytex natural rubber latex | 45% Ultra-low protein latex and related rubber materials used in dipped products and other latex applications. |
| RxAir air purifiers | 35% UV-C filterless air purification devices sold for residential, healthcare, and commercial use. |
| Replacement cartridges and accessories | 10% Replacement cartridges and related consumables for previously sold RxAir units. |
| Licensing and distribution arrangements | 10% Market development, distribution, and license-based commercialization of Vytex and related technologies. |
Vystar sells to manufacturers that use natural rubber latex in dipped goods and other rubber-intensive applications,...
- Industrial latex manufacturersprimary
Buy Vytex materials for dipped products and other latex applications where protein content and material performance matter.
- Healthcare and medical customersprimary
Buy RxAir units for air purification in environments that value germicidal UV-C performance and FDA-cleared products.
- Residential consumerssecondary
Buy RxAir residential purifiers for home air cleaning without traditional filters.
- Commercial and institutional buyerssecondary
Buy larger or commercial RxAir units for offices, facilities, and other shared spaces.
- Replacement-part customersemerging
Buy ViraTec cartridges for previously sold units, supporting the installed base.
Vystar is headquartered in the United States and its commercial activity is centered there, including product...
- •Headquartered and primarily operated in the United States
- •RxAir is sold through U.S. distributors, online, and retail channels
- •Vytex commercialization includes North American market needs
- •Contract manufacturing may be placed based on geographic demand
- •Trade policy and China tariffs can affect sourcing and costs
Vystar’s strategy centers on commercializing Vytex through trials, distribution partnerships, and licensing while...
01
Commercialize Vytex through trials and licensingmedium-term
Vytex needs customer adoption and manufacturing validation to become a scalable materials business.
02
Expand RxAir product reachshort-term
Broader product availability and channel coverage can support recurring device and cartridge sales.
03
Pursue corporate transactions for divisionsshort-term
Spinouts or sales may help separate businesses with different capital needs and commercialization paths.
Vystar faces execution risk because its businesses depend on customer trials, commercialization milestones, and...
Commercialization risk for Vytex
Vytex relies on trials, customer validation, and manufacturing-scale adoption before it can generate durable demand.
- Scope
- Industrial latex and dipped-product markets
- Materiality
- high
Product adoption risk for RxAir
Air purifier sales depend on channel execution, regulatory positioning, and customer acceptance of UV-C technology.
- Scope
- Residential, healthcare, and commercial channels
- Materiality
- high
Tariff and supply-chain risk
Trade policy and import tariffs can raise input costs and disrupt sourcing or contract manufacturing decisions.
- Scope
- Imports from China and other countries
- Materiality
- medium
Revenue recognition timing
Quarterly comparability
Stock-based compensation
Operating expense and net loss
Going-concern disclosures
Financial statement presentation and risk disclosure
Discontinued operations and divestiture accounting
Comparability across periods
: 29.4.2026